

Author: Frost Paul A A.
Publisher: Maney Publishing
ISSN: 1757-093X
Source: Pharmaceutical Programming, Vol.3, Iss.2, 2010-12, pp. : 57-63
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The use of metadata to drive dynamic programming is a common and well documented process, from Oracle® system tables to the SAS® SQL dictionary tables. Analysis and Reporting Technology (A&RT), AstraZeneca’s first truly global reporting system, extends this concept to incorporate data standards, metadata maintenance and metadata re-use; leveraging structural hierarchy (an arrangement of items, e.g. objects, names, values, categories, etc., in which the items are represented as being ‘above’, ‘below’, or ‘at the same level as’ one another and with only one ‘neighbour’ above and below each level), equivalence (assigning one object to another) and inheritance (a way to form new classes, instances of which are called objects, using classes that have already been defined. Inheritance is intended to help reuse existing code with little or no modification), together with the collection of metadata ahead of time to streamline the process and minimize resource intensive activities on the critical path to submission. We will look at the how and why of the A&RT reporting solution, process versus technology, key touch points for any reporting solution, and visions for the future. We will touch on the importance of integrating a data standardization process and organization into the reporting technology. We will discuss how adding metadata collection and import/export functionality to a reporting technology can help facilitate the validation of data standards and the production of key deliverables. Our roadmap for the future includes enhanced impact analysis, tighter integration between UNIX processing power and windows UI components, and a lifecycle management plan to ensure that our technology base remains current and our system enhancements user driven.
Related content


An agreement reached with AstraZeneca will allow
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 387, 2002-01 ,pp. :


Iressa linked to tumour haemorrhage, warns AstraZeneca
Reactions Weekly, Vol. 1, Iss. 1132, 2006-01 ,pp. :




AstraZeneca's rosuvastatin up against Pfizer's atorvastatin in the US
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 426, 2003-01 ,pp. :


DTC advertising planned for `NuvaRing', changes suggested by AstraZeneca
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 491, 2005-01 ,pp. :